Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-let-7b-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RDM0027H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Cell culture lysate, Whole blood, PBMC

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, the kit is stable until the expiration date (see label on the box)

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.39 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 8.9%

Inter-assay (Run-to-Run)

n = 5,
CV = 13.8%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-let-7b-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Immune Response, Infection and Inflammation, Oncology, Neurodegenerative disease


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

Let-7b has been found to act as a tumor suppressor, in order to halt cell proliferation, adhesion, and invasion by targeting the genes of PKA1, DIAPH2, RDX, Ras, c-myc, and HMGA2 proteins. Let-7b expression is differently regulated in breast cancer and the data reveal its possible role in DNA repair capacity during breast carcinogenesis. Similarly, miR-let-7b was shown to be significantly downregulated in osteosarcoma tissues and cell lines and the functional studies revealed that the antitumor effect of miR-let-7b was probably due to targeting and suppressing IGF1R expression.

Let-7b has differential expression patterns also in inflamed tissues compared with healthy controls. The data demonstrate that overexpression of miR-let-7b caused a marked decrease in the expression of the proinflammatory genes, whereas blocking of miR-let-7b caused a reciprocal increase in cytokine expression. Circulating miR-let-7b-5p together with miR-125b-5p function as regulators of the inflammatory response in endometriosis. It was published that up-regulation of miR-let-7b was characteristic of prostatic tumor-associated macrophages and might play a vital role in regulating macrophage polarization, thus modulating the prognosis of prostate cancer. Furthermore, results suggest that miR-let-7b contributes to the epithelial immune responses against H. pylori infection. It has also been shown that miR-let-7b may protect human mesenchymal stem cells implanted into infarcted myocardium from apoptosis and autophagy.

Moreover, miR-let-7b has been linked to neurodegeneration; elevated amounts of miR-let-7b were found in the cerebrospinal fluid of patients with Alzheimer’s disease. In addition, miR-let-7b might be a promising blood-derived miRNA biomarker in multiple sclerosis.

Summary References (10)

References to miR-let-7b-5p

  • Encarnación et al. "High DRC Levels Are Associated with Let-7b Overexpression in Women with Breast Cancer. "International journal of molecular sciences 17.6 (2016): 865.
  • Mayr, Hemann, and Bartel. "Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation." Science 315.5818 (2007): 1576-1579.
  • Hu et al. "The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer." Molecular cancer research 11.3 (2013): 240-250.
  • Zhang et al. "Let 7b acts as a tumor suppressor in osteosarcoma via targeting IGF1R." Oncology letters 17.2 (2019): 1646-1654.
  • Wang et al. "miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer." Scientific reports 6 (2016): 25602.
  • Nematian et al. "Systemic inflammation induced by microRNAs: endometriosis-derived alterations in circulating microRNA 125b-5p and Let-7b-5p regulate macrophage cytokine production." The Journal of Clinical Endocrinology & Metabolism103.1 (2017): 64-74.
  • Teng et al. "Let-7b is involved in the inflammation and immune responses associated with Helicobacter pylori infection by targeting Toll-like receptor 4." PloS one 8.2 (2013): e56709.
  • Ham et al. "let-7b suppresses apoptosis and autophagy of human mesenchymal stem cells transplanted into ischemia/reperfusion injured heart 7by targeting caspase-3." Stem cell research & therapy 6.1 (2015): 147.
  • Liu et al. "Cerebrospinal fluid CD4+ T lymphocyte-derived miRNA-let-7b can enhances the diagnostic performance of Alzheimer's disease biomarkers." Biochemical and biophysical research communications 495.1 (2018): 1144-1150.
  • Freiesleben et al. "Analysis of microRNA and gene expression profiles in multiple sclerosis: integrating interaction data to uncover regulatory mechanisms." Scientific reports 6 (2016): 34512.
Related Products Docs